Comparison of the structural changes induced by Doxorubicin and Mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex

Journal of Molecular and Cellular Cardiology

Volumn 29, Issue 9, 1997, Pages 2415-2430

  Herman, Eugene H ^a   Zhang, Jun ^a   Hasinoff, Brian B ^b   Clark Jr , John R ^c   Ferrans, Victor J ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Apoptosis; Cardiac toxicity; Doxorubicin; Iron mitoxantrone complex; Mitoxantrone; Renal toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FERRIC ION; IRON COMPLEX; LIGAND; MITOXANTRONE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; DOSE RESPONSE; ELECTRON MICROSCOPY; GASTROINTESTINAL SYMPTOM; HEART; HEART MUSCLE CELL; HISTOLOGY; INTESTINE; KIDNEY; KIDNEY TUBULE EPITHELIUM; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALIA;

EID: 0031239308     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1997.0477     Document Type: Article

References (51)

1. ALDERTON PM, GROSS J, GREEN MD, 1992. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in chronic cardiotoxicity animal model. Cancer Res 52: 194-201.
2. BASRA J, WOLF CR, BROWN JR, PATTERSON LH, 1985. Evidence for human liver mediated free-radical formation by doxorubicin and mitoxantrone. Anticancer Drug Des 1: 45-52.
3. BENJAMIN RS, 1995. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 22: 11-13.
4. BHALLA K, IBRADO AM, TOURKINA E, TANG C, GRANT S, BULLOCK G, HUANG Y, PONNATHPUR V, MAHONEY ME, 1993. High-dose mitoxantrone induces programmed cell death or aopotisis in human myeloid leukemia cells. Blood 82: 3133-3140.
5. BILLINGHAM ME, 1991. Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: Silver MD (ed.). Cardiovascular Pathology. 2nd ed. New York: Churchill Livingstone, 1465-1486.
6. BUSS JL, HASINOFF BB, 1993. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dextazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40: 86-95.
7. COLEMAN R, SILBERMANN M, GERSHON D, REZNICK AZ, 1987. Giant mitochondria in the myocardium of aging and endurance-trained mice. Gerontology 33: 34-39.
8. D'ARPA P, LIU LF, 1989. TOPOISOMERASE-TARGETING ANTITUMOUR DRUGS. Biochim Biophys Acta 989: 163-177.
9. DE ISABELLA P, CAPRANICO G, PALUMBO M, SISSI C, KRAPCHO AP, ZUNINO F, 1993. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. Mol Pharmacol 43: 715-721.
10. DOROSHOW JH, 1983. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADPH dehydrogenase. Cancer Res 43: 4543-4551.
11. DORR RT, SHIPP NG, LEE KM, 1991. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anticancer Drugs 2: 27-33.
12. DUSONCHET L, CANDILORO V, CROSTA L, RAUSA L, 1989. Isolated myocardiocytes and DNA synthesis: a possible experimental model to predict the in vivo cardiotoxicity. Pharmacol Res 21 (Suppl. 1): 25-26.
13. DUSONCHET L, CANDILORO V, CROSTA L, SANGUEDOLCE R, ARMATA MG, RAUSA L, 1991. Influence of mitoxantrone on the syntheses of DNA and proteins of mouse tissues. Tumori 77: 219-226.
14. FERRANS VJ, SANCHEZ JA, HERMAN EH, 1992a. Pathologic anatomy of animal models of anthracycline-induced cardiotoxicity. In: Muggia FM, Green MD, Speyer JL (eds). Cancer Treatment and the Heart. Baltimore: The John Hopkins University Press, 89-113.
15. FERRANS VJ, SANCHEZ JA, HERMAN EH, 1992b. Role of myocardial biopsy in the diagnosis of anthracycline toxicity. In: Muggia FM, Green MD, Speyer JL (eds). Cancer Treatment and the Heart. Baltimore: John Hopkins University Press, 198-216.
16. FISHER GR, PATTERSON LH, 1991. DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol 43: 65-68.
17. FISHER GR, GUTIERREZ PL, OLDCORNE MA, PATTERSON LH, 1992. NAD(P)H (quinone acceptor) oxidoreductase (DT-diaphorase)-mediated two-electron reduction of anthraquinone-based antitumor agents and generation of hydroxyl radicals. Biochem Pharmacol 43: 575-585.
18. FISHER GR, PATTERSON LH, GUTIERREZ PL, 1993. A comparison of free radical formation by quinone antitumour agents in MCF-7 cells and the role of NAD(P)H (quinone-acceptor) oxidoreductase (DT-diaphorase). Chem Biol Interact 88: 137-153.
19. FOX ME, SMITH PJ, 1990. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumour DNA intercalators mAMSA and mitoxantrone. Cancer Res 50: 5813-5818.
20. GAVRIELI Y, SHERMAN Y, BEN-SASSON SA, 1992. Identification of programmed cell death in-situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501.
21. GELVAN D, BERG E, SALTMAN P, SAMUNI A, 1990. Time-dependent modifications of ferric-adriamycin. Biochem Pharmacol 39: 1289-1295.
22. GOTTLIEB RA, BURLESON KO, KLONER RA, BABIOR BM, ENGLER RL, 1994. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94: 1621-1628.
23. HASINOFF BB, 1989. The interaction of the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane]; its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 26: 378-385.
24. HASINOFF BB, 1990. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane]. Agents Actions 29: 374-381.
25. HERMAN EH, EL-HAGE AN, FERRANS VJ, ARDALAN B, 1985. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol 78: 202-214.
26. HERMAN EH, EL-HAGE A, FERRANS VJ, 1988. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 92: 42-53.
27. HERMAN EH, FERRANS VJ, SANCHEZ JA, 1992. Methods of reducing the cardiotoxicity of anthracyclines. In: Muggia FM, Green MD, Speyer JL (eds). Cancer Treatment and the Heart. Baltimore: John Hopkins University Press, 114-170.
28. JAENKE RS, 1974. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest 30: 292-304.
29. JOHNSON RK, ZEE-CHENG RK, LEE WW, ACTON EM, HENRY DW, CHENG CC, 1979. Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63: 425-439.
30. KHARASCH ED, NOVAK RF, 1985. Mitoxantrone and amentantrone inhibit hydroperoxide-dependent initiation and propagation reactions in fatty acid peroxidation. J Biol Chem 260: 10645-10652.
31. KIMLER BF, MANSFIELD CM, SVOBODA DJ, COX GG, 1984. Ultrastructural evidence of cardiac damage resulting from thoracic irradiation and anthracyclines in the rat. Int J Radiat Oncol Biol Phys 10: 1465-1469.
32. KOLODZIEJCZYK P, GARNIER-SUILLEROT A, 1987. Circular dichroism study of the interaction of mitoxantrone, ametantrone and their Pd(II) complexes with deoxyribonucleic acid. Biochim Biophys Acta 926: 249-257.
33. KOLODZIEJCZYK P, RESZKA K, LOWN JW, 1988. Enzymatic oxidative activation and transformation of the antitumor agent mitoxantrone. Free Radic Biol Med 5: 13-25.
34. KRAUS B, CAIN H, 1980. Giant mitochondria in the human myocardium - morphogenesis and fate. Virchows Arch B Cell Pathol Incl Mol Pathol 33: 77-89.
35. LOWN JW, HANSTOCK CC, BRADLEY RD, SCRABA DG, 1984. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy. Mol Pharmacol 25: 178-184.
36. MALISA KL, HASINOFF BB, 1995a. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyle radicals. Arch Biochem Biophys 316: 680-688.
37. MALIZA KL, HASINOFF BB, 1995b. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys 321: 51-60.
38. MURDOCK KC, CHILD RG, FABIO PF, ANGIER RB, WALLACE RE, DURR FE, CITARELLA RV, 1979. Antitumor agents. 1. 1.4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem 22: 1024-1030.
39. MYERS CE, GIANNI L, SIMONE CB, KLECKER R, GREENE R, 1982. Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. Biochemistry 21: 1707-1712.
40. NOVAK RF, KHARASCH ED, FRANK P, RUNGE-MORRIS M, 1988. Anthracyclines, anthracenediones and anthrapyrazoles: comparison of redox cycling activity and effects on lipid peroxidation and prostoglandin production. In: Lown JW (ed.). Anthracycline and Anthracenedione-based Anticancer Agents. Amsterdam: Elsevier, 475-526.
41. PERKINS WE, SCHROEDER RL, CARRANO RA, IMONDI AR, 1984. Myocardial effects of mitoxantrone and doxorubicin in the mouse and guinea pig. Cancer Treat Rep 68: 841-847.
42. POSNER LE, DUKART G, GOLDBERG J, BERNSTEIN T, CARTWRIGHT K, 1985. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3: 123-132.
43. POWIS G, 1991. In: POWIS G and HACKER MP (eds). The Toxicity of Anticancer Drugs. New York: Pergamon Press.
44. RESZKA K, KOLODZIEJCZYK P, TSOUNGAS PG, LOWN JW, 1988. Photosensitization by antitumor agents - 6. Production of superoxide radical and hydrogen peroxide during illumination of diaminoanthracenediones in the presence of NADH in aqueous solutions: an EPR study. Photochem Photobiol 47: 625-633.
45. RIGGS CE, 1992. ANTITUMOR ANTIBIOTICS AND RELATED COMPOUNDS. In: PERRY M (ed.). The Chemotherapy Source Book. Baltimore: Williams & Wilkins, 318-358.
46. TANAKA M, ITO H, ADACHI S, AKIMOTO H, NISHIKAWA T, KASAJIMA T, MARUMO F, HIROE M, 1994. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 75: 426-433.
47. TANDLER B, HOPPEL CL, 1986. Studies on giant mitochondria. Ann N Y Acad Sci 488: 65-81.
48. UNVERFERTH DV, UNVERFERTH BJ, BALCERZAK SP, BASHORE TA, NEIDHART JA, 1983. Cardiac evaluation of mitoxantrone. Cancer Treat Rep 67: 343-350.
49. VILE GF, WINTERBOURN CC, 1989. Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study. Cancer Chemother Pharmacol 24: 105-108.
50. ZHANG J, HERMAN EH, FERRANS VJ, 1993. Dendritic cells in the heart of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187. Am J Pathol 142: 1916-1926.
51. ZHANG J, CLARK JR JR, HERMAN EH, FERRANS VJ, 1996. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol 28: 1931-1943.